Tanner Pharma Group has announced the opening of its new US operations facility in Charlotte, NC.
This purpose-built, 22,000+ sqft facility will host secondary packaging, labelling, storage and distribution capabilities for the company.
This is being done in order to meet the evolving needs of the company's pharmaceutical partners.
Pharmaceutical and biotech companies partner with Tanner Pharma Group to license and commercialise their products in challenging international markets, develop and manage their access programmes, and source comparator drugs for clinical trials and bioanalysis.
Impact on clinical trial services and global distribution
This expansion significantly bolsters Tanner’s ability to support the complex needs of clinical trials and further ensures timely and efficient delivery of critical pharmaceutical products worldwide.
With expanded temperature-controlled storage, custom-built secondary packaging and labelling rooms, and secure space for controlled drug distribution, the company is well-equipped to meet the diverse demands of the pharmaceutical industry.
Enhanced capabilities and operational efficiency
The new GDP/GMP facility is designed to strengthen operations with several key features:
- Temperature-controlled storage: Includes controlled ambient space (15°C – 25°C), refrigerated storage (2°C – 8°C), frozen storage (-20°C) and ultra-low frozen storage (-80°C).
- Operational efficiency: Features custom-built secondary labelling and packaging rooms, segregated and secure gowning areas, separate shipping and receiving docks, and mapped and monitored temperature and humidity.
- Security: Includes redundant facility-wide power supply, 24-hour security, CCTV, and 24/7 motion detection and recording.
- Compliance: Complies with EU GDP standards and holds NC 3PL License, multiple NC Wholesale Distribution Licenses and wholesale distribution licenses in 20 US states.
"This facility not only enhances our ability to serve our partners but also supports the pursuit of our core mission to improve patients’ lives by enabling access to medicines," said Steve Scalia, President of Tanner Pharma Group